Immix Biopharma (IMMX) Cash from Financing Activities (2021 - 2026)

Immix Biopharma (IMMX) has 6 years of Cash from Financing Activities data on file, last reported at -$37561.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to -$37561.0; the trailing twelve-month figure through Mar 2026 stood at $106.2 million (changed N/A YoY), and the FY2025 full-year result was $107.4 million, up 573.33% from the prior year.
• Cash from Financing Activities slipped to -$37561.0 in Q1 2026, from $95.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $95.7 million in Q4 2025 to a low of -$105963.0 in Q2 2022.
• A 5-year average of $12.8 million and a median of $2.9 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 228.71% in 2022 and surged 13311.62% in 2024, its largest moves.
• Tracing IMMX's Cash from Financing Activities over 5 years: stood at $424276.0 in 2022, then surged by 38.28% to $586692.0 in 2023, then soared by 2618.39% to $15.9 million in 2024, then soared by 499.86% to $95.7 million in 2025, then tumbled by 100.04% to -$37561.0 in 2026.
• Business Quant data shows IMMX's Cash from Financing Activities at -$37561.0 in Q1 2026, $95.7 million in Q4 2025, and $10.6 million in Q3 2025.